【プレスリリースメモ】 RNAi関係 (2013.4.28)  

<Alnylam Pharmaceuticals>
Alnylam to Webcast Presentation at 12th Annual Needham Healthcare Conference(2013.4.23)

<Altogen Labs>
Altogen Labs Offers Pre-Clinical CRO Services to Accelerate Pre-Clinical Research Needs(2013.4.26)

Mesoblast Reports Positive Interim Results in Phase 2 Trial of Proprietary Adultn Stem Cell for Intervertebral Disc Repair(2013.4.22)

<Arrowhead Research>
Arrowhead to Present at Master Investor 2013(2013.4.24)
Arrowhead to Present at Needham Healthcare Conference(2013.4.24)

Asuragen announces publication on standardization of BCR-ABL1 testing on the international scale(2013.4.23)

<CytRx Corporation>
CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma(2013.4.23)

<Enzon Pharmaceuticals>
Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividends(2013.4.23)

<Galena Biopharma>
Galena Biopharma to Present at the 12th Annual Needham Healthcare Conference(2013.4.24)

<iCo Therapeutics>
iCo Therapeutics Announces Year End 2012 Financial Results(2013.4.25)

<Isis Pharmaceuticals>
Isis Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference(2013.4.22)
ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy(2013.4.23)

<Mirna Therapeutics>
A Phase I Study of MRX34 Given Intravenously in Patients With Unresectable Primary Liver Cancer or Metastatic Cancer With Liver Involvement ← MRX34はDDSとしてSMARTICLE技術を使用

<OncoGenex Technologies>
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference(2013.4.23)
OncoGenex to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013(2013.4.25)

<OPKO Health>
OPKO Health To Acquire PROLOR Biotech(2013.4.24)

Investor Conference Call Details - 24 April 2013(2013.4.23)
Recording of Investor Conference Call - 24 April 2013(2013.4.24)
Phase 3 Clinical Trial in Bronchiectasis (B305) Fails Primary Endpoint; Meets Key Secondary Endpoints on Efficacy and Safety(2013.4.24)

<Regulus Therapeutics>
Regulus to Present at 12th Annual Needham Healthcare Conference(2013.4.24)

<RXi Pharmaceuticals>
RXi Pharmaceuticals Appoints H. Paul Dorman and Curtis Lockshin, Ph.D. to Board of Directors(2013.4.22)

<Sarepta Therapeutics>
Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013(2013.4.26)

<Valeant Pharmaceuticals>
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.(2013.4.22)
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.(2013.4.23)
Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.(2013.4.24)
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.(2013.4.25)

Vical CEO to Participate in Cancer Immunotherapy Panel at BIO International Convention(2013.4.22)

子宮頸がんの前がん病変治療ワクチン(CIN 治療ワクチン)の漢方薬による増強効果を解明(2013.4.23)

[ 2013/04/28 20:06 ] プレスリリース | TB(0) | CM(0)

07 ≪│2018/08│≫ 09
- - - 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 -